Pathios Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $25.3Mattributed |
|---|---|
| Latest round | series-b, $25.3M, 2024-04-01attributed |
| Founded | 2018 |
| Headquarters | Oxford, UK |
| Industry | bio |
| Stage | series-b+ |
| Website | pathiostherapeutics.com |
Pathios Therapeutics is a clinical-stage oncology and immunology company targeting GPR65, an acid-sensing receptor on immune cells. It serves patients with solid tumors who could benefit from a new immunotherapy. It inhibits GPR65 to fix immune dysfunction in the acidic tumor microenvironment.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-01 | series-b | $25.3M | undisclosed |
Detected tech stack
WordPress 6.9.4, Modernizr, Yoast SEO 27.5, reCAPTCHA, Google Analytics, Google Hosted Libraries, Google Maps, Google Tag Manager, Flywheel 5.1.0, DoubleClick Floodlight, Contact Form 7 6.1.5, CookieYes 3.4.2
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $25.3M | attributed | eu-startups named as publisher. No document URL on file. |
| Total raised $25.3M | attributed | eu-startups named as publisher. No document URL on file. |
| Company existence | self-reported | pathiostherapeutics.com, read 2026-05-07 |
| Description | self-reported | pathiostherapeutics.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.